Neoplasia/BPH

	Efficacy and safety of cytoreductive nephrectomy combined with thrombectomy in metastatic renal cell carcinoma with venous tumor thrombus: a real-world study based on inverse probability of treatment weighting. World J Urol Shi C, Peng C, Song J, Jiao Q, Chen Y, Yang Z, Lv D, Zhang X, Gu L, Ma X, Huang Q. PMID: 42472396 [PubMed - indexed for MEDLINE]
	PSMA PET/CT in contemporary prostate cancer management: From initial staging to biochemical recurrence. Hell J Nucl Med Panagiotidis E, Angelidis G, Koinis F, Valotassiou V, Psimadas D, Tsivaka D, Tsougos I, Kotsakis A, Georgoulias P. PMID: 42472322 [PubMed - indexed for MEDLINE]
	Expert consensus recommendations for the management of biochemical recurrence in prostate cancer: a Delphi study across clinical scenarios. Clin Transl Oncol López Campos F, Couñago F, Vallejo JA, Vilaseca A, Pérez Fentes D. PMID: 42471494 [PubMed - as supplied by publisher]
	Lutetium-177-PSMA radioligand therapy in metastatic hormone-sensitive prostate cancer: A systematic review of efficacy, safety, and combination strategies. Urol Oncol McGrath J, Willis R, Balaji S, Ishiyama Y, Sceats H, Bandyk M, Balaji KC. PMID: 42471290 [PubMed - as supplied by publisher]
	Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment. Cancer Treat Res Commun Ahrens M, Haanen J, Albiges L, Goupil MG, Boleti E, Gravis G, Fléchon A, Grimm MO, Bedke J, Barthélémy P, Castellano D, Mellado B, Ivanyi P, Rottey S, Flörcken A, Suárez C, Maroto JP, Grünwald V, Oosting S, Kopecky J, Zschäbitz S, Boegemann M, Buchler T, Niegisch G, Goebell PJ, Waddell T, Joly F, Priou F, Retz M, Siemer S, Zimmermann U, Deckbar D, Burkholder I, Stöhr C, Hartmann A, Bergmann L, Interdisciplinary Renal Cell Carcinoma Working Group of the DKG (IAGN). PMID: 42470850 [PubMed - as supplied by publisher]
	Risk of second primary malignancies after bladder cancer diagnosed at a young age: a SEER population-based analysis. Int J Clin Oncol Eigner E, Fazaa N, Nsair A, Atallah M, Amiel GE, Hoffman A, Malshy K. PMID: 42470523 [PubMed - as supplied by publisher]
	Shared Genetics of Kidney Function Traits and Bladder Cancer: A Genome-Wide Cross-Trait Analysis. Cancer Med Lin Y, Xiang N, Yang Y, Huang S, Su S, Fu T, Luo Y, Wang Z, Shi R, Zheng T, Liao B, Huang J. PMID: 42470241 [PubMed - indexed for MEDLINE]
	Estimating the heritability of longitudinal rate-of-change: genetic insights into PSA velocity in prostate cancer-free individuals. Biostatistics Zhang P, Wang X, Shi J, Albert PS. PMID: 42470129 [PubMed - indexed for MEDLINE]
	A case report of primary prostate intravascular large B-cell lymphoma. Medicine (Baltimore) Yuan F, Liu Q, Ding W, Nie J, Wang X. PMID: 42470066 [PubMed - indexed for MEDLINE]
	Multifocal xanthogranulomatous inflammation of the urinary tract mimicking metastatic urothelial carcinoma: A case report. Medicine (Baltimore) Zhang Z, Zhao Y, Li Z. PMID: 42469998 [PubMed - indexed for MEDLINE]
	Impact of immunotherapy as a monotherapy or in combination with conventional therapies on regulatory T-cell (Treg) modulation in prostate cancer: a systematic review. BMC Cancer Akinnola OO, Olaniyan AI, Adeboye BA, Akinyosoye AD. PMID: 42469702 [PubMed - as supplied by publisher]
	Emerging antibody-drug conjugates in metastatic castration-resistant prostate cancer. Urol Oncol Nguyen CB, Reichert ZR. PMID: 42469055 [PubMed - as supplied by publisher]
	Reply to Antonio Cigliola, Andrea Necchi, and Umberto Capitanio's Letter to the Editor Re: Metastasis-directed Therapy with or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.024. Eur Urol Sherry AD, To V, Msaouel P, Neeson P, Tang C, Siva S. PMID: 42469054 [PubMed - as supplied by publisher]
	Artificial Intelligence in Digital Pathology for Prostate Cancer Detection: FDA Clearance and Real-World Implementation. J Clin Pathol Rainer Q, Sun Y, Vyas M, Kopach P, Gondim D, Muthukumarana V, Thaker H, Deshpande V. PMID: 42468971 [PubMed - as supplied by publisher]
	Radiation-induced erectile dysfunction in prostate cancer: A systematic review of pathophysiology, clinical radiobiology, and predictive modeling. Phys Med Saraei P, Bagheri A, Danyaei A, Jafari M, Salek R, Hosseini S, Obeidavi I, Chegeni N. PMID: 42468493 [PubMed - as supplied by publisher]
	Prognostic role of the Glasgow prognostic score and modified Glasgow prognostic score in patients with renal cell carcinoma undergoing immunotherapy: a meta-analysis. Clinics (Sao Paulo) Zhang X, Li X, Xie Y, Shi N. PMID: 42468376 [PubMed - as supplied by publisher]
	Patient-Reported Outcome Design and Analysis in Randomized Controlled Trials of Renal Cell Carcinoma: A Systematic Review. Clin Genitourin Cancer Chen D, Chen S, Sun D, Chow E, Lee SF, Wong HCY, Raman S. PMID: 42468185 [PubMed - as supplied by publisher]
	Automated volumetric iRECIST-inspired CT assessment of treatment response to dual immune checkpoint inhibition in metastatic renal cell carcinoma: A feasibility study. Eur J Radiol Kraaijveld RCJ, Ma B, Suelmann BBM, Wessels FJ, Ragusi MAA, de Keizer B, Gilhuijs KGA. PMID: 42468161 [PubMed - as supplied by publisher]
	Occupational exposure to metals and prostate cancer: CAPLIFE study. Cancer Epidemiol Olmedo-Requena R, Villanueva-Piqueras PJ, Lozano-Lorca M, Castillo-Hermoso MÁ, Jiménez-Moleón JJ, Salcedo-Bellido I. PMID: 42468082 [PubMed - as supplied by publisher]
	A Phase 2 Trial of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) for the Treatment of Non-Muscle Invasive BCG Unresponsive Urothelial Carcinoma of the Bladder. J Urol DeCastro GJ, Joffe BI, Stein MN, Abate-Shen C, Miles CH, Gray JM, Anderson CB, Lenis AT, McKiernan JM. PMID: 42467648 [PubMed - as supplied by publisher]

Articles 1 - 20 / 189872

Page 1 of 9494



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy